Hepatitis B Vaccine (Recombinant)
- Generic Name
- Hepatitis B Vaccine (Recombinant)
- Brand Names
- Engerix-B, Heplisav-B, Pediarix, Recombivax, Twinrix, Vaxelis, Heplisav B, Fendrix, PreHevbri
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- IFJ010MNE4
- Background
Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada.
...
- Indication
Active immunization against hepatitis B virus infection.
...
- Associated Conditions
- Hepatitis A, Viral Hepatitis B
- Associated Therapies
- -
New Methods to Measure the Immune Response to Hepatitis B Vaccine
Phase 4
Completed
- Conditions
- First Posted Date
- 2013-04-01
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 21
- Registration Number
- NCT01821547
- Locations
- 🇬🇧
Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom
Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2013-05-22
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 236
- Registration Number
- NCT00316303
- Locations
- 🇺🇸
University of Maryland, Department of Psychaitry, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath